Study guide
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs
Key Takeaways Explain This Topic AI
Automated Office Blood Pressure (AOBP) thresholds ( ≥ 135 / 85 \ge 135/85 ≥ 135/85 mmHg) differ from routine manual office measurements ( ≥ 140 / 90 \ge 140/90 ≥ 140/90 mmHg) and diabetes targets ( ≥ 130 / 80 \ge 130/80 ≥ 130/80 mmHg) under Canadian guidelines.
Red blood cell indices differentiate microcytic (MCV < 80 fL: iron deficiency, thalassemia), normocytic (MCV 80 to 100 fL: anemia of chronic disease, acute blood loss), and macrocytic (MCV > 100 fL: B12/folate deficiency, hydroxyurea, methotrexate) anemias.
Serum calcium must be mathematically corrected for hypoalbuminemia using the formula: Corrected Calcium = Measured Calcium + 0.02 * (40 - Albumin in g/L).
High anion gap metabolic acidosis (AG > 12 mmol/L) results from unmeasured organic anions (MUDPILES / GOLD MARK: methanol, uremia, DKA, paraldehyde, isoniazid/iron, lactic acidosis, ethylene glycol, salicylates).
Acute hyperkalemia with electrocardiographic abnormalities requires immediate intravenous calcium gluconate or calcium chloride for myocardial membrane stabilization before deploying intracellular potassium-shifting therapies.
Last updated: August 2026
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs
Exam Focus: Pharmacists must interpret subjective clinical signs, physical examination findings, and objective laboratory values reported in Standard International (SI) units (e.g., mmol/L \text{mmol/L} mmol/L , μ mol/L \mu\text{mol/L} μ mol/L , g/L \text{g/L} g/L , L/L \text{L/L} L/L ). Mastery of diagnostic reference ranges, physiological compensation mechanisms, biomarker kinetics, and drug-induced laboratory alterations is essential for detecting Drug Therapy Problems (DTPs) and establishing safe, effective monitoring plans on the PEBC Evaluating Examination.
Vital Signs and Physical Assessment
Vital signs represent the first-line objective clinical markers of homeostatic stability, systemic perfusion, and autonomic balance.
Blood Pressure (BP) Measurement Standards
Hypertension Canada establishes strict clinical protocols for blood pressure measurement to minimize white-coat effects and ensure diagnostic accuracy:
Automated Office Blood Pressure (AOBP): Preferred measurement modality in clinical practice. The patient rests alone in a quiet room while an automated oscillometric device takes 4 to 5 consecutive readings. Diagnostic threshold for hypertension: ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg .
Non-Automated / Manual Office Blood Pressure (OBP): Auscultatory or manual oscillometric measurement in the presence of a healthcare provider. Diagnostic threshold for hypertension: ≥ 140 / 90 mmHg \ge 140/90\text{ mmHg} ≥ 140/90 mmHg .
Ambulatory Blood Pressure Monitoring (ABPM): 24-hour mean threshold ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg ; awake/daytime mean ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg .
Home Blood Pressure Monitoring (HBPM): Duplicate morning and evening measurements over 7 days (discarding day 1); average threshold ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg .
Diabetes Target: Target blood pressure for patients with diabetes mellitus is < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg .
Assessment Modality Hypertensive Diagnostic Threshold Clinical Pearls
Automated Office (AOBP) ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg Eliminates white-coat response; preferred Canadian standard
Manual Office (OBP) ≥ 140 / 90 mmHg \ge 140/90\text{ mmHg} ≥ 140/90 mmHg Requires proper cuff bladder encircling ≥ 80 % \ge 80\% ≥ 80% of arm circumference
Ambulatory 24-Hour (ABPM) ≥ 130 / 80 mmHg \ge 130/80\text{ mmHg} ≥ 130/80 mmHg Gold standard for confirming nocturnal non-dipping and masked hypertension
Home Monitoring (HBPM) ≥ 135 / 85 mmHg \ge 135/85\text{ mmHg} ≥ 135/85 mmHg Evaluates treatment response; 7-day protocol with first day discarded
Diabetes Mellitus Target < 130 / 80 mmHg < 130/80\text{ mmHg} < 130/80 mmHg Strict renal and microvascular protective target
Heart Rate, Respiration, Oxygenation, and Temperature
Heart Rate (HR): Normal resting range is 60 to 100 beats/min (bpm) 60\text{ to }100\text{ beats/min (bpm)} 60 to 100 beats/min (bpm) . Bradycardia ( < 60 bpm < 60\text{ bpm} < 60 bpm ) is commonly induced by beta-blockers, non-dihydropyridine calcium channel blockers (diltiazem, verapamil), digoxin, and acetylcholinesterase inhibitors (donepezil). Tachycardia ( > 100 bpm > 100\text{ bpm} > 100 bpm ) occurs in sepsis, hypovolemia, anemia, hyperthyroidism, sympathomimetic use, and anticholinergic toxicity.
Respiratory Rate (RR): Normal adult range is 12 to 20 breaths/min 12\text{ to }20\text{ breaths/min} 12 to 20 breaths/min . Tachypnea ( > 20 breaths/min > 20\text{ breaths/min} > 20 breaths/min ) signals respiratory compensation for metabolic acidosis, hypoxemia, pulmonary embolism, or acute heart failure.
Pulse Oximetry ( SpO 2 \text{SpO}_2 SpO 2 ): Normal room air saturation is 95 % to 100 % 95\%\text{ to }100\% 95% to 100% . In chronic hypercapnic respiratory failure (severe COPD), target oxygen saturation is adjusted to 88 % to 92 % 88\%\text{ to }92\% 88% to 92% to avoid suppressing hypoxic respiratory drive and causing acute carbon dioxide narcosis.
Body Temperature: Normal core body temperature is 36.5 ∘ C to 37.5 ∘ C 36.5^\circ\text{C to }37.5^\circ\text{C} 36. 5 ∘ C to 37. 5 ∘ C . Clinical fever is defined as a single oral temperature ≥ 38.3 ∘ C \ge 38.3^\circ\text{C} ≥ 38. 3 ∘ C or sustained temperature ≥ 38.0 ∘ C \ge 38.0^\circ\text{C} ≥ 38. 0 ∘ C for over 1 hour. Hypothermia ( < 35.0 ∘ C < 35.0^\circ\text{C} < 35. 0 ∘ C ) can occur in severe sepsis, advanced hypothyroidism (myxedema coma), and central nervous system depressant overdose.
Hematology: Complete Blood Count (CBC) and Differential
The Complete Blood Count provides quantitative and qualitative information regarding erythroid, myeloid, and megakaryocytic cell lines. +-------------------------------------------------------------------------+
- | COMPLETE BLOOD COUNT (CBC) SCHEMATIC |
- +-------------------------------------------------------------------------+
- | |
- | [Erythrocytes] ------------------> Hemoglobin (Hgb), Hematocrit (Hct) |
- | | MCV: Microcytic vs Macrocytic |
- | v RDW: Anisocytosis Indicator |
- | [Platelets] ---------------------> Thrombocytes (150 to 400 x 10^9/L) |
- | | HIT Screening (4Ts Score) |
- | v |
- | [Leukocytes] --------------------> Total WBC (4.0 to 11.0 x 10^9/L) |
- | |-- Neutrophils (Segs/Bands) -> Bacterial infection, Left shift |
- | |-- Lymphocytes ------------> Viral infections, CLL |
- | |-- Eosinophils ------------> Drug allergies (DRESS), Parasites |
- | |-- Monocytes & Basophils --> Chronic inflammation, Histamine |
- | |
- +-------------------------------------------------------------------------+
- Red Blood Cell Indices and Anemia Classification
Laboratory Parameter Reference Range (SI Units) Clinical Significance
Hemoglobin (Hgb) Male: 135 to 175 g/L 135\text{ to }175\text{ g/L} 135 to 175 g/L ; Female: 120 to 160 g/L 120\text{ to }160\text{ g/L} 120 to 160 g/L Primary oxygen-carrying metalloprotein. Decreased in anemia, hemorrhage, hemolysis, and marrow failure.
Hematocrit (Hct) Male: 0.40 to 0.50 L/L 0.40\text{ to }0.50\text{ L/L} 0.40 to 0.50 L/L ; Female: 0.36 to 0.46 L/L 0.36\text{ to }0.46\text{ L/L} 0.36 to 0.46 L/L Proportion of whole blood occupied by erythrocytes (approximately 3 × Hgb 3 \times \text{Hgb} 3 × Hgb in g/dL \text{g/dL} g/dL equivalents).
Mean Corpuscular Volume (MCV) 80 to 100 fL 80\text{ to }100\text{ fL} 80 to 100 fL Average volume of an individual erythrocyte; central parameter for morphologic classification of anemia.
Red Cell Distribution Width (RDW) 11.5 % to 14.5 % 11.5\%\text{ to }14.5\% 11.5% to 14.5% Quantitative index of erythrocyte size variation (anisocytosis). Elevated in iron deficiency ( > 15 % > 15\% > 15% ); normal in uncomplicated thalassemia trait.
Reticulocyte Count 0.5 % to 2.0 % 0.5\%\text{ to }2.0\% 0.5% to 2.0% ( 25 to 75 × 10 9 / L 25\text{ to }75 \times 10^9/\text{L} 25 to 75 × 1 0 9 / L ) Immature erythrocytes containing residual ribosomal RNA. Evaluates bone marrow erythropoietic response.
Morphologic Differential Diagnosis of Anemia
Microcytic Anemia ( MCV < 80 fL \text{MCV} < 80\text{ fL} MCV < 80 fL ):
Iron Deficiency Anemia (IDA): Low serum ferritin ( < 30 μ g/L < 30\,\mu\text{g/L} < 30 μ g/L or < 100 μ g/L < 100\,\mu\text{g/L} < 100 μ g/L in inflammatory states), low transferrin saturation ( < 20 % < 20\% < 20% ), high total iron-binding capacity (TIBC), and elevated RDW.
Thalassemia Minor/Trait: Impaired globin chain synthesis, normal/elevated ferritin, normal RDW, prominent microcytosis disproportionate to mild anemia.
Sideroblastic Anemia: Defective heme synthesis (can be induced by isoniazid, linezolid, alcohol, or lead poisoning); ringed sideroblasts on marrow biopsy.
Normocytic Anemia ( MCV 80 to 100 fL \text{MCV } 80\text{ to }100\text{ fL} MCV 80 to 100 fL ):
Anemia of Chronic Disease / Inflammation: Elevated hepcidin blocks iron export via ferroportin; normal to elevated ferritin, low TIBC, low transferrin saturation.
Chronic Kidney Disease (CKD): Deficient renal erythropoietin production by peritubular capillary interstitial cells.
Hemolytic Anemia: High reticulocyte count ( > 2.5 % > 2.5\% > 2.5% ), elevated unconjugated bilirubin, elevated lactate dehydrogenase (LDH), and low/undetectable haptoglobin.
Macrocytic Anemia ( MCV > 100 fL \text{MCV} > 100\text{ fL} MCV > 100 fL ):
Megaloblastic (Impaired DNA Synthesis): Vitamin B12 (cobalamin) deficiency (elevated methylmalonic acid and homocysteine; neurological symptoms like subacute combined degeneration) or Folate deficiency (elevated homocysteine with normal methylmalonic acid). Drug causes include methotrexate, hydroxyurea, trimethoprim, zidovudine, and 5-fluorouracil.
Non-Megaloblastic: Alcohol abuse, hepatic disease, reticulocytosis (reticulocytes are larger than mature RBCs), and severe hypothyroidism.
White Blood Cell (WBC) Differential and Absolute Neutrophil Count
Total Leukocytes normal reference range is 4.0 to 11.0 × 10 9 / L 4.0\text{ to }11.0 \times 10^9/\text{L} 4.0 to 11.0 × 1 0 9 / L .
Neutrophils ( 2.0 to 7.5 × 10 9 / L 2.0\text{ to }7.5 \times 10^9/\text{L} 2.0 to 7.5 × 1 0 9 / L / 50 % to 70 % 50\%\text{ to }70\% 50% to 70% ): Primary phagocytes against bacterial infections. A "left shift" indicates an increased proportion of immature band forms ( > 10 % > 10\% > 10% ), reflecting acute bone marrow response to bacterial invasion or severe systemic inflammation.
Absolute Neutrophil Count (ANC): ANC = Total WBC (cells/ μ L) × ( % Segmented Neutrophils + % Band Forms 100 ) \text{ANC} = \text{Total WBC (cells/}\mu\text{L)} \times \left(\frac{\%\text{ Segmented Neutrophils} + \%\text{ Band Forms}}{100}\right) ANC = Total WBC (cells/ μ L) × ( 100 % Segmented Neutrophils + % Band Forms )
Neutropenia Classifications: Mild ( 1.0 to 1.5 × 10 9 / L 1.0\text{ to }1.5 \times 10^9/\text{L} 1.0 to 1.5 × 1 0 9 / L ), Moderate ( 0.5 to 1.0 × 10 9 / L 0.5\text{ to }1.0 \times 10^9/\text{L} 0.5 to 1.0 × 1 0 9 / L ), Severe / Agranulocytosis ( < 0.5 × 10 9 / L < 0.5 \times 10^9/\text{L} < 0.5 × 1 0 9 / L ). Severe neutropenia represents an emergency requiring protective isolation and rapid empiric broad-spectrum antimicrobial coverage if febrile.
Drug-Induced Agranulocytosis: High-risk medications include clozapine (mandates strict weekly-to-monthly hematologic monitoring), methimazole / propylthiouracil (PTU) , carbamazepine , and cytotoxic chemotherapy.
Eosinophils ( 0.04 to 0.40 × 10 9 / L 0.04\text{ to }0.40 \times 10^9/\text{L} 0.04 to 0.40 × 1 0 9 / L / 1 % to 4 % 1\%\text{ to }4\% 1% to 4% ): Elevated in IgE-mediated allergic conditions, parasitic infections, and severe cutaneous adverse reactions (SCARs), such as Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS syndrome; commonly triggered by allopurinol, carbamazepine, lamotrigine, and sulfonamides).
Platelets and Thrombocytopenia
Normal platelet count is 150 to 400 × 10 9 / L 150\text{ to }400 \times 10^9/\text{L} 150 to 400 × 1 0 9 / L .
Thrombocytopenia ( < 150 × 10 9 / L < 150 \times 10^9/\text{L} < 150 × 1 0 9 / L ): Spontaneous bleeding risk escalates dramatically when platelets fall below 20 × 10 9 / L 20 \times 10^9/\text{L} 20 × 1 0 9 / L ( < 10 × 10 9 / L < 10 \times 10^9/\text{L} < 10 × 1 0 9 / L mandates urgent platelet transfusion).
Heparin-Induced Thrombocytopenia (HIT Type II): Immune-mediated adverse reaction caused by IgG antibodies directed against platelet factor 4 (PF4)-heparin complexes, causing platelet activation, consumption, and a paradoxical prothrombotic state. Diagnosed using the 4Ts Score (Thrombocytopenia > 50 % > 50\% > 50% drop, Timing 5 to 10 days post-exposure, Thrombosis confirmed, no oTher cause). Management: Immediately stop all heparin products (unfractionated and LMWH) and initiate a non-heparin direct thrombin inhibitor (argatroban, bivalirudin) or fondaparinux.
Serum Electrolytes and Mineral Homeostasis
Electrolytes maintain cellular resting membrane potential, neuromuscular transmission, and osmotic equilibrium. +-------------------------------------------------------------------------+
- | SERUM ELECTROLYTE SPECTRUM |
- +-------------------------------------------------------------------------+
- | |
- | Sodium (Na+): 135 to 145 mmol/L --> Osmolality, Volume, Brain |
- | Potassium (K+): 3.5 to 5.0 mmol/L --> Cardiac Membrane Excitability |
- | Chloride (Cl-): 98 to 106 mmol/L --> Acid-Base Anion Balance |
- | Bicarbonate: 22 to 28 mmol/L --> Extracellular Buffer System |
- | Calcium (Ca2+): 2.15 to 2.55 mmol/L -> Neuromuscular, Bone, QT |
- | Magnesium (Mg2+): 0.70 to 1.00 mmol/L -> Enzymatic Cofactor, TdP |
- | Phosphate (PO4): 0.80 to 1.45 mmol/L -> Energy (ATP), CKD-MBD |
- | |
- +-------------------------------------------------------------------------+
- Sodium ( Na + \text{Na}^+ Na + : 135 to 145 mmol/L 135\text{ to }145\text{ mmol/L} 135 to 145 mmol/L )
Hyponatremia ( < 135 mmol/L < 135\text{ mmol/L} < 135 mmol/L ):
Hypovolemic: Renal losses (diuretics) vs extra-renal losses (vomiting, diarrhea, third-spacing).
Euvolemic: Syndrome of Inappropriate Antidiuretic Hormone (SIADH), commonly triggered by SSRIs, SNRIs, carbamazepine, oxcarbazepine, antipsychotics, and cyclophosphamide. Diagnosed by low serum osmolality ( < 275 mOsm/kg < 275\text{ mOsm/kg} < 275 mOsm/kg ), high urine osmolality ( > 100 mOsm/kg > 100\text{ mOsm/kg} > 100 mOsm/kg ), and elevated urine sodium ( > 40 mmol/L > 40\text{ mmol/L} > 40 mmol/L ). Treatment involves fluid restriction and removal of offending medications.
Hypervolemic: Congestive heart failure, hepatic cirrhosis, nephrotic syndrome.
Rate of Correction Safety Rule: Chronic hyponatremia must not be corrected faster than 8 to 10 mmol/L 8\text{ to }10\text{ mmol/L} 8 to 10 mmol/L in 24 hours to prevent irreversible Osmotic Demyelination Syndrome (ODS) (formerly central pontine myelinolysis).
Hypernatremia ( > 145 mmol/L > 145\text{ mmol/L} > 145 mmol/L ): Characterized by free water deficit (diabetes insipidus, inadequate access to water). Rapid correction risks cerebral edema.
Potassium ( K + \text{K}^+ K + : 3.5 to 5.0 mmol/L 3.5\text{ to }5.0\text{ mmol/L} 3.5 to 5.0 mmol/L )
Hypokalemia ( < 3.5 mmol/L < 3.5\text{ mmol/L} < 3.5 mmol/L ): Induced by loop/thiazide diuretics, beta-2 agonists, insulin, corticosteroids, and amphotericin B. Electrocardiographic (ECG) signs include flattened or inverted T waves, prominent U waves, ST-segment depression, and ventricular tachyarrhythmias. Hypomagnesemia must be corrected concurrently; low magnesium impairs renal tubular Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase activity, causing ongoing renal potassium wasting.
Hyperkalemia ( > 5.0 mmol/L > 5.0\text{ mmol/L} > 5.0 mmol/L ): Induced by ACE inhibitors, ARBs, mineralocorticoid receptor antagonists (spironolactone, eplerenone), trimethoprim, potassium-sparing diuretics, NSAIDs, and calcineurin inhibitors (tacrolimus, cyclosporine). ECG signs progress through tall peaked T waves, PR-interval prolongation, QRS widening, loss of P waves, and fatal sine-wave ventricular fibrillation/asystole.
Emergency Management Protocol for Hyperkalemia with ECG Changes
Myocardial Membrane Stabilization: Intravenous Calcium Gluconate ( 10 % 10\% 10% , 10 mL 10\text{ mL} 10 mL over 2 to 3 minutes) or Calcium Chloride. Acts within 1 to 3 minutes without altering serum potassium concentration.
Intracellular Potassium Shifting (Immediate Reduction):
Regular Insulin ( 10 units 10\text{ units} 10 units IV) administered with Dextrose ( 50 mL 50\text{ mL} 50 mL of 50 % 50\% 50% dextrose, D50W \text{D50W} D50W ) to prevent hypoglycemia.
Inhaled Salbutamol ( 10 to 20 mg 10\text{ to }20\text{ mg} 10 to 20 mg nebulized, 4 × 4 \times 4 × standard bronchodilator dose).
Intravenous Sodium Bicarbonate ( 50 mmol 50\text{ mmol} 50 mmol IV) if concurrent metabolic acidosis exists.
Potassium Elimination (Sustained Removal):
Loop Diuretics (e.g., Furosemide IV) if patient possesses adequate renal perfusion.
Cation Exchange Resins / Potassium Binders: Sodium Polystyrene Sulfonate (SPS), Patiromer, or Sodium Zirconium Cyclosilicate (SZC).
Hemodialysis: Definitive therapy for refractory hyperkalemia or end-stage renal disease.
Calcium ( Ca 2 + \text{Ca}^{2+} Ca 2 + : 2.15 to 2.55 mmol/L 2.15\text{ to }2.55\text{ mmol/L} 2.15 to 2.55 mmol/L ) and Albumin Correction
Approximately 40 % to 50 % 40\%\text{ to }50\% 40% to 50% of total serum calcium is bound to albumin. In patients with hypoalbuminemia, total measured serum calcium appears falsely low while physiologically active ionized calcium ( 1.15 to 1.35 mmol/L 1.15\text{ to }1.35\text{ mmol/L} 1.15 to 1.35 mmol/L ) remains normal. Corrected Calcium (mmol/L) = Measured Total Calcium (mmol/L) + 0.02 × [ 40 − Serum Albumin (g/L) ] \text{Corrected Calcium (mmol/L)} = \text{Measured Total Calcium (mmol/L)} + 0.02 \times [40 - \text{Serum Albumin (g/L)}] Corrected Calcium (mmol/L) = Measured Total Calcium (mmol/L) + 0.02 × [ 40 − Serum Albumin (g/L) ]
Hypocalcemia: Caused by hypoparathyroidism, vitamin D deficiency, CKD-MBD, bisphosphonates, cinacalcet, and denosumab. Manifests with neuromuscular hyper-excitability, tetany, Chvostek's sign (facial twitch on tapping facial nerve), Trousseau's sign (carpal spasm with BP cuff inflation), and prolonged QT interval.
Hypercalcemia: Caused by primary hyperparathyroidism, malignancy (PTHrP secretion or osteolytic bone metastases), thiazide diuretics, lithium, and vitamin D toxicity. Manifests with "bones, stones, abdominal groans, and psychiatric overtones," alongside shortened QT interval.
Magnesium ( Mg 2 + \text{Mg}^{2+} Mg 2 + : 0.70 to 1.00 mmol/L 0.70\text{ to }1.00\text{ mmol/L} 0.70 to 1.00 mmol/L )
Hypomagnesemia ( < 0.70 mmol/L < 0.70\text{ mmol/L} < 0.70 mmol/L ): Triggered by proton pump inhibitors (PPIs; long-term impairment of TRPM6 active intestinal transport), loop/thiazide diuretics, aminoglycosides, cisplatin, and chronic alcohol use. Clinically causes refractory hypokalemia, hypocalcemia (impaired PTH release), neuromuscular tremor, seizures, and Torsades de Pointes (TdP) .
Arterial Blood Gas (ABG) and Acid-Base Interpretation
Acid-base homeostasis maintains arterial pH within the strict physiological boundary of 7.35 to 7.45 7.35\text{ to }7.45 7.35 to 7.45 .
ABG Parameter Reference Range Physiological Significance
pH 7.35 to 7.45 7.35\text{ to }7.45 7.35 to 7.45 Negative log of hydrogen ion concentration; < 7.35 < 7.35 < 7.35 acidosis, > 7.45 > 7.45 > 7.45 alkalosis
pCO 2 \text{pCO}_2 pCO 2 35 to 45 mmHg 35\text{ to }45\text{ mmHg} 35 to 45 mmHg ( 4.7 to 6.0 kPa 4.7\text{ to }6.0\text{ kPa} 4.7 to 6.0 kPa ) Respiratory component; volatile acid regulated rapidly by alveolar ventilation
HCO 3 − \text{HCO}_3^- HCO 3 − 22 to 26 mmol/L 22\text{ to }26\text{ mmol/L} 22 to 26 mmol/L Metabolic component; base regulated by renal tubular reabsorption and secretion
pO 2 \text{pO}_2 pO 2 80 to 100 mmHg 80\text{ to }100\text{ mmHg} 80 to 100 mmHg ( 10.6 to 13.3 kPa 10.6\text{ to }13.3\text{ kPa} 10.6 to 13.3 kPa ) Arterial oxygen tension evaluating pulmonary alveolar diffusion efficiency
Systematic 4-Step Acid-Base Assessment
Evaluate the pH: Determine whether primary disturbance is Acidemia ( pH < 7.35 \text{pH} < 7.35 pH < 7.35 ) or Alkalemia ( pH > 7.45 \text{pH} > 7.45 pH > 7.45 ).
Identify the Primary Driver:
If pH \text{pH} pH and pCO 2 \text{pCO}_2 pCO 2 move in opposite directions → \to → Primary Respiratory Disorder.
If pH \text{pH} pH and HCO 3 − \text{HCO}_3^- HCO 3 − move in the same direction → \to → Primary Metabolic Disorder.
Assess Compensatory Response: The respiratory system responds in minutes via minute ventilation changes; the renal metabolic system takes 24 to 72 hours to alter bicarbonate retention.
Calculate the Serum Anion Gap (for Metabolic Acidosis): Serum Anion Gap = [ Na + ] − ( [ Cl − ] + [ HCO 3 − ] ) \text{Serum Anion Gap} = [\text{Na}^+] - ([\text{Cl}^-] + [\text{HCO}_3^-]) Serum Anion Gap = [ Na + ] − ([ Cl − ] + [ HCO 3 − ])
Normal Anion Gap: 8 to 12 mmol/L 8\text{ to }12\text{ mmol/L} 8 to 12 mmol/L (reflects unmeasured serum proteins like albumin).
High Anion Gap Metabolic Acidosis (HAGMA; AG > 12 mmol/L \text{AG} > 12\text{ mmol/L} AG > 12 mmol/L ): Caused by accumulation of unmeasured organic acids. Classic mnemonic MUDPILES / GOLD MARK :
- M ethanol (formic acid)
- U remia (renal failure; phosphate, sulfate retention)
- D iabetic Ketoacidosis ( β \beta β -hydroxybutyrate, acetoacetate)
- P ropylene glycol / Paraldehyde
- I soniazid / I ron
- L actic acidosis (hypoperfusion, metformin toxicity, sepsis)
- E thylene glycol (oxalic acid, glycolic acid; envelope-shaped urine calcium oxalate crystals)
- S alicylates (aspirin toxicity; causes early respiratory alkalosis followed by severe HAGMA)
Normal Anion Gap (Hyperchloremic) Metabolic Acidosis (NAGMA; AG ≤ 12 mmol/L \text{AG} \le 12\text{ mmol/L} AG ≤ 12 mmol/L ): Caused by direct bicarbonate loss with compensatory chloride retention. Etiologies: severe diarrhea, renal tubular acidosis (RTA), carbonic anhydrase inhibitors (acetazolamide, topiramate).
- Renal and Hepatic Function Diagnostics
- Renal Function Biomarkers +-------------------------------------------------------------------------+
- | RENAL FUNCTION EVALUATION MATRIX |
- +-------------------------------------------------------------------------+
- | |
- | Serum Creatinine (SCr): 50 to 110 umol/L -> Muscle breakdown byproduct|
- | BUN / Serum Urea: 2.5 to 8.0 mmol/L -> Amino acid catabolism |
- | BUN : SCr Ratio: > 20:1 suggests Pre-Renal Azotemia |
- | eGFR (CKD-EPI): > 90 mL/min/1.73m^2 (Normal Stage G1) |
- | Urine ACR: < 2.0 mg/mmol (Normal albumin excretion) |
- | 2.0 to 20.0 mg/mmol (Microalbuminuria) |
- | > 20.0 mg/mmol (Overt Macroalbuminuria) |
- | |
- +-------------------------------------------------------------------------+
Serum Creatinine (SCr: 50 to 110 μ mol/L 50\text{ to }110\,\mu\text{mol/L} 50 to 110 μ mol/L ): Endogenous byproduct of skeletal muscle creatine metabolism eliminated entirely by glomerular filtration (with minor tubular secretion). Underestimates renal impairment in frail, sarcopenic, elderly patients due to reduced muscle mass.
Blood Urea Nitrogen / Serum Urea ( 2.5 to 8.0 mmol/L 2.5\text{ to }8.0\text{ mmol/L} 2.5 to 8.0 mmol/L ): Reflects urea synthesized in the liver from protein catabolism. Reabsorbed passively in proximal tubules with water. A BUN : SCr \text{BUN}:\text{SCr} BUN : SCr ratio > 20 : 1 > 20:1 > 20 : 1 (in mg/dL \text{mg/dL} mg/dL equivalents) or Urea ( mmol/L ) : SCr ( mmol/L ) > 100 : 1 \text{Urea}(\text{mmol/L}):\text{SCr}(\text{mmol/L}) > 100:1 Urea ( mmol/L ) : SCr ( mmol/L ) > 100 : 1 indicates Pre-Renal Azotemia (volume depletion, heart failure dehydration).
Urinalysis and Cast Morphology:
Muddy Brown Granular Casts: Diagnostic hallmark of Acute Tubular Necrosis (ATN) .
Red Blood Cell (RBC) Casts: Hallmark of Glomerulonephritis (post-streptococcal, IgA nephropathy, lupus nephritis).
White Blood Cell (WBC) Casts: Diagnostic of Acute Interstitial Nephritis (AIN) or acute pyelonephritis.
Hyaline Casts: Non-specific; seen in concentrated urine, dehydration, or post-strenuous exercise.
Hepatic Function and Enzyme Diagnostics
Biomarker Reference Range Diagnostic Interpretation
Alanine Aminotransferase (ALT) 10 to 40 U/L 10\text{ to }40\text{ U/L} 10 to 40 U/L Hepatocellular injury. Cytosolic enzyme highly specific to hepatocytes.
Aspartate Aminotransferase (AST) 10 to 35 U/L 10\text{ to }35\text{ U/L} 10 to 35 U/L Present in liver, myocardium, and skeletal muscle. AST : ALT > 2 : 1 \text{AST}:\text{ALT} > 2:1 AST : ALT > 2 : 1 strongly indicates alcoholic liver disease.
Alkaline Phosphatase (ALP) 30 to 120 U/L 30\text{ to }120\text{ U/L} 30 to 120 U/L Cholestasis or bone turnover. Located in biliary canalicular membranes and osteoblasts.
Gamma-Glutamyl Transferase (GGT) 5 to 50 U/L 5\text{ to }50\text{ U/L} 5 to 50 U/L Hepatic-specific enzyme. Elevated alongside ALP confirms biliary/hepatic origin (distinguishes hepatic cholestasis from bone pathology).
Total Bilirubin 3 to 20 μ mol/L 3\text{ to }20\,\mu\text{mol/L} 3 to 20 μ mol/L End-product of heme catabolism. Jaundice clinically visible when total bilirubin > 35 to 50 μ mol/L > 35\text{ to }50\,\mu\text{mol/L} > 35 to 50 μ mol/L .
Direct (Conjugated) Bilirubin 0 to 5 μ mol/L 0\text{ to }5\,\mu\text{mol/L} 0 to 5 μ mol/L Elevation ( > 50 % > 50\% > 50% of total) indicates intra- or extra-hepatic cholestasis, biliary obstruction, or hepatitis.
Serum Albumin 35 to 50 g/L 35\text{ to }50\text{ g/L} 35 to 50 g/L True hepatic synthetic function (half-life ≈ 20 days \approx 20\text{ days} ≈ 20 days ). Decreased in chronic cirrhosis, malnutrition, nephrotic syndrome.
Prothrombin Time / INR INR 0.9 to 1.2 \text{INR } 0.9\text{ to }1.2 INR 0.9 to 1.2 Evaluates vitamin K-dependent clotting factors (II, VII, IX, X) synthesized by liver. Factor VII has a short half-life ( 6 hours 6\text{ hours} 6 hours ); INR is the most sensitive marker of acute hepatic failure.
- Cardiac, Inflammatory, and Coagulation Biomarkers
- Cardiac Biomarkers
High-Sensitivity Cardiac Troponin (hs-cTnI / hs-cTnT): Preferred gold standard biomarker for myocardial injury and necrosis. Rises within 2 to 4 hours post-infarction, peaks at 12 to 24 hours, and remains elevated for 7 to 14 days. Serial testing showing dynamic rise and fall confirms acute myocardial infarction.
B-Type Natriuretic Peptide (BNP / NT-proBNP): Released by ventricular myocytes in response to wall stress and volume expansion. BNP > 100 pg/mL > 100\text{ pg/mL} > 100 pg/mL or NT-proBNP > 300 pg/mL > 300\text{ pg/mL} > 300 pg/mL supports acute heart failure decompensation. Pharmacology Pearl: Neprilysin degrades BNP but does not degrade NT-proBNP. In patients taking sacubitril/valsartan , BNP levels are artificially elevated; NT-proBNP must be used for clinical assessment.
Inflammatory Biomarkers
C-Reactive Protein (CRP) & hs-CRP: Acute-phase reactant synthesized by the liver under IL-6 stimulation. hs-CRP < 1.0 mg/L < 1.0\text{ mg/L} < 1.0 mg/L indicates low cardiovascular risk, 1.0 to 3.0 mg/L 1.0\text{ to }3.0\text{ mg/L} 1.0 to 3.0 mg/L average risk, and > 3.0 mg/L > 3.0\text{ mg/L} > 3.0 mg/L high risk.
Erythrocyte Sedimentation Rate (ESR): Indirect measure of acute phase proteins (fibrinogen). Normal < 15 mm/hr < 15\text{ mm/hr} < 15 mm/hr (men), < 20 mm/hr < 20\text{ mm/hr} < 20 mm/hr (women). Elevated in temporal arteritis, polymyalgia rheumatica, osteomyelitis, and systemic lupus erythematosus.
Procalcitonin (PCT): Peptide precursor of calcitonin produced by parenchymal tissue in response to bacterial endotoxins and inflammatory cytokines (IL-1 β \beta β , TNF- α \alpha α ). Used to guide antibiotic initiation and cessation in lower respiratory tract infections and sepsis; low levels ( < 0.25 μ g/L < 0.25\,\mu\text{g/L} < 0.25 μ g/L ) argue against bacterial infection.
Coagulation Panel
International Normalized Ratio (INR): Standardized ratio of prothrombin time monitoring the extrinsic and common pathways (Factors VII, X, V, II, fibrinogen). Therapeutic target for warfarin is 2.0 to 3.0 2.0\text{ to }3.0 2.0 to 3.0 for non-valvular atrial fibrillation, deep vein thrombosis, and pulmonary embolism; 2.5 to 3.5 2.5\text{ to }3.5 2.5 to 3.5 for mechanical mitral prosthetic heart valves.
Activated Partial Thromboplastin Time (aPTT): Measures intrinsic and common pathways (Factors XII, XI, IX, VIII, X, V, II, fibrinogen). Normal 25 to 35 seconds 25\text{ to }35\text{ seconds} 25 to 35 seconds . Used to monitor unfractionated heparin (UFH) infusions (therapeutic range typically 1.5 to 2.5 × 1.5\text{ to }2.5 \times 1.5 to 2.5 × control baseline, or 60 to 85 seconds 60\text{ to }85\text{ seconds} 60 to 85 seconds ).
Anti-Factor Xa Assay: Quantitative measure for monitoring low-molecular-weight heparins (LMWH; therapeutic peak target 0.6 to 1.0 units/mL 0.6\text{ to }1.0\text{ units/mL} 0.6 to 1.0 units/mL for twice-daily enoxaparin), unfractionated heparin, and direct oral factor Xa inhibitors (apixaban, rivaroxaban, edoxaban).
D-Dimer: Degradation product of cross-linked fibrin. Highly sensitive ( > 95 % > 95\% > 95% ) with a high negative predictive value; a normal D-dimer ( < 0.50 μ g/mL < 0.50\,\mu\text{g/mL} < 0.50 μ g/mL or < 500 ng/mL < 500\text{ ng/mL} < 500 ng/mL ) effectively rules out deep vein thrombosis (DVT) and pulmonary embolism (PE) in low-to-intermediate pre-test probability patients.